Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock PriceInvestors Business Daily • 05/16/25
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?Zacks Investment Research • 05/16/25
Novo Nordisk CEO to step down amid pressure from obesity drug competitionProactive Investors • 05/16/25
Instant View: Wegovy-maker Novo Nordisk ousts CEO as competition in obesity drug market heats upReuters • 05/16/25
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo NordiskGlobeNewsWire • 05/16/25
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 MonthsThe Motley Fool • 05/16/25
Septerna Stock Surges on Oral Obesity Drug Deal With Novo NordiskZacks Investment Research • 05/15/25
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapiesProactive Investors • 05/14/25
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes DrugsBenzinga • 05/14/25
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna SkyrocketingInvestors Business Daily • 05/14/25
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatmentsReuters • 05/14/25